Pembrolizumab shows real promise against head and neck cancer, study suggests

Related posts:

1. Combining targeted drug with chemotherapy offers longer life to b-cell cancer patients Because of the significant benefit found in combining the targeted drug ibrutinib with standard chemotherapy for relapsed chronic lymphocytic leukemia or small lymphocytic lymphoma, an interim analysis has closed the international HELIOS phase III clinical trial. ...
2. Altered pain processing in patients with cognitive impairment People with dementia and other forms of cognitive impairment (CI) have altered responses to pain, with many conditions associated with increased pain sensitivity, concludes a new research review. ...
3. End European agreements with tobacco industry designed to curb smuggling, urge experts The agreements drawn up between the European Union and the four major transnational tobacco companies, to crack down on cigarette smuggling and recoup lost tax revenues, are failing to meet their stated aims, concludes research. ...
4. Targeted drug can ‘diminish the suffering’ of myelofibrosis Use of the targeted agent pacritinib significantly reduced the symptoms and burden of advanced myelofibrosis in patients, says a researcher who co-led PERSIST-1, the worldwide phase 3 clinical trial that tested the therapy. Specifically, pacritinib substantially reduced severe enlargement of the spleen, a typical feature of advanced myelofibrosis, in more than 20 percent of patients and alleviated debilitating side effects in more than 46 percent. ...
5. Anticoagulant medications: Newer, easier to manage medications may not always be the best choice If you are over age 75, and taking an anticoagulant, the old standard may be the gold standard, Mayo Clinic researchers and collaborators have determined. ...